Libera Bio CEO Olivier Jarry talks to Proactive about the Santiago de Compostela, Spain-based preclinical stage biotechnology company's recent progress on its potential new oncology treatments. Jarry says the privately-held group has been receiving interest on partnering opportunities from top pharma companies to advance its MPN technology, a nanotechnology that targets tumor and metastatic cells and delivers small and large molecules to intracellular targets, towards clinical trials.
Libera Bio receiving interest around its tumor cell targeting MPN tech from top pharma companies
